Logo small

Opportunity for seriously ill patients with mitral valve regurgitation

MedExpress Team


Published June 3, 2024 08:59

Opportunity for seriously ill patients with mitral valve regurgitation - Header image
fot. iStock
Up to half of patients with severe symptomatic mitral valve regurgitation are not referred for surgery because of the risks of the procedure. For them, an innovative tricuspid valve made from porcine pericardium may be a chance for treatment. - This is a chance of life for this group of patients, the last type of treatment that can be offered to them," says Professor Mariusz Kuśmierczyk, head of the Department of Heart, Thoracic and Transplant Surgery at the University Clinical Center of Warsaw Medical University. Unfortunately, the product is currently not covered by reimbursement.

Mitral regurgitation (MR) is the most common form of mitral valve disease. MR can be primary or secondary, and the preferred treatment strategy varies depending on the etiology. The prevalence of MR in the general population is about 2 percent. Clinically significant MR (moderate or greater severity) occurs in less than 1 percent of people under the age of 50, but already in more than 10 percent of people over the age of 70.

MR is often associated with heart failure (secondary MR)...

Content locked

To gain access to the complete English section of the, kindly reach out to us at [email protected].

If you already have an account, please log in

Szukaj nowych pracowników

Dodaj ogłoszenie już za 4 zł dziennie*.

* 4 zł netto dziennie. Minimalny okres ekspozycji ogłoszenia to 30 dni.

Read also